LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

LLY

1,014.52

-3.15%↓

JNJ

243.43

-0.55%↓

ABBV

224.55

-3.14%↓

NVS

165.62

-1.16%↓

MRK

120.01

-3.14%↓

Search

Avita Therapeutics Inc

Atvērts

4.93 -2.57

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.85

Max

5.11

Galvenie mērījumi

By Trading Economics

Ienākumi

1.6M

-12M

Pārdošana

554K

18M

EPS

-0.536

Peļņas marža

-65.968

Darbinieki

226

EBITDA

1.6M

-9.7M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

-16.51% downside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 7. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

25M

149M

Iepriekšējā atvēršanas cena

7.5

Iepriekšējā slēgšanas cena

4.93

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

Avita Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 25. febr. 23:25 UTC

Karstas akcijas

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026. g. 25. febr. 23:15 UTC

Peļņas

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026. g. 25. febr. 23:54 UTC

Tirgus saruna

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026. g. 25. febr. 23:47 UTC

Peļņas

Ferrovial 4Q Net EUR197M >FER.MC

2026. g. 25. febr. 23:45 UTC

Peļņas

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026. g. 25. febr. 23:42 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026. g. 25. febr. 23:38 UTC

Tirgus saruna

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Company's Business Operations Remain Normal >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026. g. 25. febr. 23:25 UTC

Peļņas

Trip.com FY EPS CNY47.67 >TCOM

2026. g. 25. febr. 23:06 UTC

Peļņas

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026. g. 25. febr. 23:01 UTC

Peļņas

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026. g. 25. febr. 23:00 UTC

Tirgus saruna
Peļņas

Global Equities Roundup: Market Talk

2026. g. 25. febr. 23:00 UTC

Tirgus saruna
Peļņas

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026. g. 25. febr. 22:56 UTC

Tirgus saruna
Peļņas

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026. g. 25. febr. 22:43 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026. g. 25. febr. 22:40 UTC

Tirgus saruna
Peļņas

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026. g. 25. febr. 22:40 UTC

Peļņas

Karoon Energy Says Search for New CFO Well Advanced

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says CFO Ray Church to Leave Company

2026. g. 25. febr. 22:39 UTC

Peļņas

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026. g. 25. febr. 22:38 UTC

Peļņas

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Salīdzinājums

Cenas izmaiņa

Avita Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

-16.51% uz leju

Prognoze 12 mēnešiem

Vidējais 4.5 USD  -16.51%

Augstākais 5.5 USD

Zemākais 3.5 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Avita Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

1

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

8.83 / 9.77Atbalsts un pretestība

Īstermiņā

Very Strong Bearish Evidence

Vidējā termiņā

Bullish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat